Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial

This prospective, randomised, double-blind, placebo-controlled trial was done at the Infectious Feto-Maternal Clinic of Rabin Medical Center (Petach Tikvah, Israel). Pregnant women aged 18 years or older, with serological evidence of a primary cytomegalovirus infection acquired either periconceptionally or during the first trimester of pregnancy, were randomly assigned to oral valaciclovir (8 g per day, twice daily) or placebo from enrolment until amniocentesis at 21 or 22 gestational weeks. Findings suggest that valaciclovir is effective in reducing the rate of fetal cytomegalovirus infection after maternal primary infection acquired early in pregnancy. Early treatment of pregnant women with primary infection might prevent termination of pregnancies or delivery of infants with congenital cytomegalovirus. 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31868-7/fulltext?utm_source=MHTF+Subscribers&utm_campaign=c59a9ffe75-EMAIL_CAMPAIGN_2018_07_27_03_30_COPY_01&utm_medium=email&utm_term=0_8ac9c53ad4-c59a9ffe75-183804741